ClinicalTrials.gg
RecruitingNCT07272434Updated Dec 9, 2025

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

A Phase 3 interventional study of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) and Placebo (Saline solution) in Respiratory Syncytial Virus (RSV), sponsored by MAXVAX Biotechnology Limited Liability Company. Recruiting at 8 sites in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by MAXVAX Biotechnology Limited Liability Company · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25,000
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.

Read the detailed description

A total of 25000 adults aged 60 years and above will be enrolled, stratified into 60-69 and ≥70 years of age. All Participants will randomly receive investigational vaccine or placebo at a ratio of 1:1. Efficacy and safety will be assessed in all Participants, while immunogenicity will be assessed in a subset of 1200 Participants in a selected trial site.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)
03

In context

Lead sponsor

MAXVAX Biotechnology Limited Liability Company is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A male or female can provide legal identification at the time of enrollment, and is 60 years of age or older (women are required to be infertile).

    (Note: Women with infertility include those who have been menopausal or have undergone sterilization (including hysterectomy, bilateral salpingectomy, bilateral oophorectomy, etc.)

  2. Be able to understand the trial procedures, risks and benefits and voluntarily agree to participate in the study and sign an .
  3. Be able to participate in all scheduled visits and comply with the protocol requirements
  4. Participants with stable health conditions considered by the investigator. Stable health conditions refer to patients with chronic diseases whose conditions are stable (regardless of whether they have received specific treatment or not), such as diabetes, hypertension, , asthma, etc. If the researcher determines that the condition is stable, they may be allowed to participate in this trial.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following exclusion criteria will not be allowed to enter the study (if the number of participants is not yet met, if the criteria described in "*" are met during screening, repeated screening may be performed)

  1. *Axillary temperature>37.3℃.
  2. History of RSV infection within 6 months before enrollment.
  3. *New onsets of respiratory tract infection symptoms like cough, sputum, shortness of breath, wheezing, fever, runny nose or nasal congestion within 7 days before enrollment.
  4. *Acute diseases or acute exacerbation of chronic disease within 3 days before vaccination.
  5. *Within 3 days before enrollment, antipyretic and analgesic drugs (except enteric-coated aspirin tablets for the prevention of cardiovascular and cerebrovascular diseases) and antihistamines were used
  6. Those who are allergic to the known components in the test vaccine [saponin (QS-21), dioleoyl phosphatidylcholine (DOPC), cholesterol, sucrose, sodium dihydrogen phosphate, anhydrous sodium dihydrogen phosphate, polysorbate 80, sodium chloride, hydrochloric acid and sodium hydroxide] Those who have a history of severe allergies after any vaccination or medication use [such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), severe urticaria, etc.] or serious adverse reactions.
  7. Asplenia or functional asplenia, and any condition leading to asplenia or splenectomy.
  8. Those who have had or are currently suffering from malignant tumors (except for clinically cured carcinoma in situ and papillary thyroid carcinoma).
  9. Patients are diagnosed with diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and autoimmune thyroid disease.
  10. Persons with known or suspected immunodeficiency disorders [e.g. primary or secondary immunodeficiency, or diagnosed with congenital or acquired immunodeficiency, infection or /cytotoxic agent therapy (e.g. cancer chemotherapy, organ transplantation or autoimmune disease treatment) resulting in confirmed or suspected immunosuppression or immunodeficiency].
  11. According to the investigator's assessment,there is any disease that may make intramuscular injections unsafe, such as a history of thrombocytopenia or other coagulation disorders.
  12. Those who have a history or are currently suffering from severe clinical diseases that have not been cured (such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, respiratory system diseases, diabetes with complications, major surgeries, etc.) and may affect the evaluation of the trial.
  13. Those who have had or are currently suffering from thrombotic diseases.
  14. Patients with a history of untreated TB or active TB at enrollment.
  15. *Hypertension with poor medication control (on-site blood pressure measurement before vaccination: systolic blood pressure≥150mmHg and/or diastolic blood pressure≥100mmHg).
  16. Those with severe arrhythmias (such as atrial fibrillation).
  17. Those with a history or family history of convulsions, epilepsy, congenital brain hypoplasia, mental illness, etc., or a history of brain nerve tissue damage caused by other serious neurological diseases (such as brain tumors, cerebral hemorrhage, brain infections, chemical drug poisoning, etc.).
  18. Use of any experimental or unapproved product (drug, vaccine or medical device) other than the vaccine used in this trial or participate in other clinical trials within 30 days prior to enrollment or during the trial period.
  19. *Within 14 days prior to enrollment, any non- has been administered, or within 28 days, a live vaccine or nucleic acid vaccine has been administered.
  20. Has received the RSV vaccine before.
  21. Use of immunoglobulin and/or any blood preparation or plasma derivative, such as gamma globulin or intravenous human immunoglobulin, within 3 months prior to enrollment or plan to use during the trial
  22. Within the 3 months prior to enrollment or if it is expected to be used for a long period during the trial (continuous for more than 14 days), immunosuppressive agents or other immunomodulatory drugs (such as long-term use of systemic for ≥ 14 days, with a dose of ≥ 20mg/day prednisone or equivalent prednisone dose; local medications are allowed, such as ointments, eye drops, inhalants or nasal sprays, but the local medication dosage must not exceed the recommended dosage in the instructions)
  23. Long-acting immunomodulatory drugs (such as infliximab) were used within 6 months before enrollment or during the planned trial period.
  24. The researchers determined that the drinking behavior and/or drug abuse history that might affect the assessment of the trial (Note: within the last three months, men had an average of more than 14 standard drinks per week, and women had an average of more than 7 standard drinks per week; 1 standard drink contained 14g of alcohol, such as 360mL of beer or 45mL of 40% alcohol spirit or 150ml of wine.) Drug abuse refers to the repeated and excessive use of drugs with dependent characteristics or potential for dependence, which is not related to recognized medical needs and falls under non-medical purpose drug use.
  25. Planned move to a location that will prohibit participating in the trial until study end;
  26. Any condition that, in the opinion of the investigator, may affect the safety of the participant or the evaluation of the study results.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25,000 participants (estimated)

Study arms

  • Experimental
    Vaccine Group

    Participants will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), by IM injection into the deltoid region of the arm.

    Biological: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

  • Placebo comparator
    Placebo Group

    Participants will receive single dose of placebo, by IM injection into the deltoid region of the arm.

    Biological: Placebo (Saline solution)

Interventions

06

What researchers measure

Primary outcomes

  1. The first-time incidence rate per person-year of Lower Respiratory Tract Disease (LRTD).

    A case caused by RSV-A and/or RSV-B as confirmed by Reverse Transcription-Polymerase Chain Reaction(RT-PCR).

    Time frame: From 14 days after vaccination until the end of the first RSV epidemic season,assessed up to 12 months.

Secondary outcomes

  1. The first-time incidence rate per person-year of Acute Respiratory Illness (ARI).

    A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.

    Time frame: From 14 days after vaccination until the end of the first RSV epidemic season,assessed up to 12 months.

  2. The first-time incidence rate per person-year of Severe Lower Respiratory Tract Disease (sLRTD).

    A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.

    Time frame: From 14 days after vaccination until the end of the first RSV epidemic season,assessed up to 12 months.

  3. The first-time incidence rate per person-year of LRTD.

    A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.

    Time frame: After vaccination, during the second RSV epidemic season,assessed up to 12 months.

  4. The first-time incidence rate per person-year of ARI.

    A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.

    Time frame: After vaccination, during the second RSV epidemic season,assessed up to 12 months.

  5. The first-time incidence rate per person-year of sLRTD.

    A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.

    Time frame: After vaccination, during the second RSV epidemic season,assessed up to 12 months.

  6. The first-time incidence rate per person-year of LRTD.

    A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.

    Time frame: From 14 days after vaccination until the end of the second RSV epidemic season,assessed up to 24 months.

  7. The first-time incidence rate per person-year of ARI.

    A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.

    Time frame: From 14 days after vaccination until the end of the second RSV epidemic season,assessed up to 24 months.

  8. The first-time incidence rate per person-year of sLRTD.

    A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.

    Time frame: From 14 days after vaccination until the end of the second RSV epidemic season,assessed up to 24 months.

  9. Geometric Mean Titers (GMT) of Neutralizing Antibody against RSV-serotype A and RSV-serotype B.

    Measured by Virus Neutralization Test.

    Time frame: At 14 days,1,12,24 and 36 months after vaccination

  10. Geometric Mean Fold Rise (GMFR) of Neutralizing Antibody against RSV-serotype A and RSV-serotype B

    Measured by Virus Neutralization Test.

    Time frame: At 14 days,1,12,24 and 36 months after vaccination

  11. Geometric Mean Concentrations (GMC) of RSV-PreF specific IgG Antibody against RSV-serotype A and RSV-serotype B

    Measured by ELISA.

    Time frame: At 14 days,1,12,24 and 36 months after vaccination

  12. GMFR of RSV-PreF specific IgG Antibody against RSV-serotype A and RSV-serotype B

    Measured by ELISA.

    Time frame: At 14 days,1,12,24 and 36 months after vaccination

  13. Incidence, Intensity and Causality of adverse events(AEs)

    An AE includes any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Within 30 days after vaccination

  14. Incidence, Intensity and Causality of solicited AEs

    Solicited AEs include solicited local and general symptoms; Assessed solicited local AEs at injection site are pain, erythema, swelling, induration and itching; Assessed solicited general symptoms include fever, fatigue, headache, myalgia, nausea, vomiting, diarrhea, arthralgia and hypersensitivity.

    Time frame: Within 7 days after vaccination

  15. Incidence, Intensity and Causality of unsolicited AEs

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation participants temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: Within 30 days after vaccination

  16. Incidence and Causality of Severe adverse events(SAEs)

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in persistent or significant disability/incapacity or are congenital anomaly/birth defect.

    Time frame: Up to 12 months post vaccination

  17. Incidence and Causality of Adverse event of special interest (AESI)

    Adverse events of special interest include potential immune-mediated diseases and atrial fibrillation.

    Time frame: Up to 12 months post vaccination

07

Study locations

5 of 8 sites recruiting
  • Guangdong Provincial Center for Disease Control and Prevention
    Guangzhou, Guangdong 511400, China
    Not yet recruiting
  • Hebei Provincial Center for Disease Control and Prevention
    Shijiazhuang, Hebei 050021, China
    Active, not recruiting

    Not enrolling at this site.

  • Henan Center for Disease Control and Prevention
    Zhengzhou, Henan 450016, China
    Recruiting
  • Hubei Provincial Center for Disease Control and Prevention
    Wuhan, Hubei 430079, China
    Recruiting
  • Hunan Provincial Center for Disease Control and Prevention
    Changsha, Hunan 410005, China
    Recruiting
  • Shaanxi Provincial Center for Disease Control and Prevention
    Xi'an, Shaanxi 710054, China
    Recruiting
  • Shandong Province Centers for Disease Control and Prevention
    Jinan, Shandong 250014, China
    Active, not recruiting

    Not enrolling at this site.

  • Sichuan Center for Disease Control and Prevention
    Chengdu, Sichuan 610041, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jul 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Dec 9, 2025
StartActual
Oct 22, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07272434
Lead sponsor
MAXVAX Biotechnology Limited Liability Company
Collaborators
Henan Center for Disease Control and Prevention, Hunan Provincial Center for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, Shaanxi Provincial Center for Disease Control and Prevention, Guangdong Center for Disease Prevention and Control, Shandong Province Centers for Disease Control and Prevention, Sichuan Center for Disease Control and Prevention, Hebei CDC ,China
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
Oct 22, 2025
Primary completion
Jul 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Dec 9, 2025

Study contacts

LiangHao Zhang
Contact
lianghao.zhang@maxvax.cn
+86 18971498772
Yanxia Wang
principal investigator · Henan Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHO cell

Start the discussion